Clinical Research

A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - RADIANT-4

Principal Investigator: Daniel Vaena, MD

Participants in this study have been diagnosed with cancer and have advanced nonfunctional neuroendocrine tumors. This is a voluntary study to find out if the drug everolimus (Afinitor®) is sage and has beneficial effects in people who have this disease. About 279 patients will join in this study at around 120 research clinics in several countries around the world.

Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

Principal Investigator:Brian Link, MD

Participants in this study have been diagnosed with aggressive B-Cell lymphoma. The purpose of this research study is to compare the good and/or bad effects of an experimental approach to treating the disease. Approximately 9 people will take part in this study conducted by investigators at the University of Iowa. Involvement in the chemotherapy regimen, may last between 9 to 24 weeks. After completing the study treatment portion, the study doctor will ask participants to schedule follow-up exams for at least 5 years.

A Phase 2 Study of MLN8237 in Advanced / Metastatic Sarcoma

Principal Investigator: Mohammed Milhem, MD

Participants in this research study have sarcoma that has spread or recurred.  The purpose of this research study is to find out what effects, good and/or bad, an experimental drug called MLN8237 has on participants and their sarcoma.

MLN8237 is a new investigational drug currently being tested for treatment of sarcoma. This study is approved and sponsored by the National Cancer Institute (NCI). An investigational drug is a medication that has not been approved for use by the U.S. Food and Drug Administration (FDA). The drug is only available in a clinical trial.

Approximately 15 people will take part in this study conducted by investigators at the University of Iowa.  Up to 135 subjects will take part in this study at serveral cancer centers nationwide. This includes up to about 30 subjects at Memorial Sloan-Kettering Cancer Center.

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy, MCL-2001

Principal Investigator:Lori Rosenstein, MD

Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.

Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Principal Investigator: Lori Rosenstein, MD

Participants in this study have been diagnosed with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). There are two treatment groups, one will receive the study drug called ibrutinib and the second group will receive a placebo. The purpose of the study is to assess the effects (both good and bad) of ibrutinib in patients with CLL or SLL and whether the CLL or SLL responds to this treatment.